Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-019-0170-z
Abstract: In 2018, the FDA approved 19 new drug and biologic applications, 38 supplemental drug and biologic applications and 4 biosimilar applications in oncology. These advances in anticancer therapy included a landmark approval of the first… read more here.
Keywords: real time; histology agnostic; new molecular; molecular entity ... See more keywords
Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1079909
Abstract: Background The development of novel therapies for patients with sarcoma is challenging due to the rarity and diversity of these mesenchymal neoplasms. Hence, histology-agnostic approvals can be of particular interest for the treatment of patients… read more here.
Keywords: sarcoma; bone; soft tissue; histology agnostic ... See more keywords